With the newly-released 2020 ADS/RACGP Australian diabetes treatment guideline presents new treatment opportunities for Australian clinicians and their patients with diabetes. In this program, you will get to know the most current diabetes management guidelines, and cover the clinical considerations of cardiovascular risk, heart failure, hypertension, obesity and renal function.
With a focus on how to individualise diabetes treatment regimens based on patients’ risk profiles and comorbidities, this program covers how to differentiate between the different classes of glucose-lowering medicines as they pertain to specific clinical situations.
This program is supported by independent educational grants provided by Boehringer Ingelheim and Eli Lilly.